Finance entity
earnings is the sole category represented across all 1 tracked stories. Arcturus Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6.1 in the same window.
Last mentioned: Mar 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Arcturus Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. We currently track 1 Finance story that mention Blueprint Medicines, all published on March 2, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Blueprint Medicines. Shared-story counts are live from our verified record — not editorial picks.
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.
Blueprint Medicines is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
